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Cell Proliferation in Human Arteries 
David Gordon, MD 
Department of Pathology, University of Michigan, Ann Arbor, Michigan 
The development and progression of human atherosclerosis appears to be associated with 
low levels of cell proliferation and with proliferative activity seen in both smooth muscle 
cells and monocytelmacrophages. The time courses and patterns of cell proliferation in this 
disease are just beginning to be addressed. 
During the development of atherosclerotic plaques, the 
progressive accumulation of intimal smooth muscle tis- 
sue, with its associated extracellular matrix compo- 
nents, has been assumed to be secondary to the 
proliferation of smooth muscle cells in the intima (l- 
3). In recent years this has prompted a search for “the 
responsible growth factor” in human arteries and in 
experimental animal model systems. What may not 
have been anticipated is the presence of several growth 
factors in the arterial wall, some of which-such as 
platelet-derived growth factor (PDGF) -A and -B iso- 
forms, basic fibroblast growth factor (bFGF), and 
others-have also been demonstrated in human 
arterial tissues (4-10). In at least rat models of balloon 
catheter-induced arterial injury and subsequent intimal 
thickening, antibodies to bFGF and to PDGF have 
shown inhibitory effects on arterial smooth muscle rep- 
lication and on intimal development, with the anti- 
bFGF antibodies seemingly having the more potent 
antiproliferative effect (9,ll). Perhaps in the future, 
similar studies in humans will elucidate those growth 
factors, which appear to be responsible for at least the 
proliferative response that occurs after balloon angio- 
plasty, often culminating in a restenotic lesion (12-14). 
In any case, the current important question for hu- 
man atherogenesis might be: Which of several growth 
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factors is most responsible for proliferation in 
atherosclerosis? 
Although no direct data are available on this ques- 
tion in human atherosclerosis, an equally basic ques- 
tion remains: What is the extent of cell proliferation in 
human atherosclerosis? Some data do exist here (Table 
1). Previous studies by Villaschi, and colleagues Spag- 
noli, (15,16) using ex vivo tritiated thymidine labeling 
on freshly obtained human arteries indicated very low 
rates of cell proliferation (0%-0.09% of cells), which 
approximates that seen in normal adult rat arteries 
(0.04%) (17). Recently, using an antibody to the pro- 
liferating cell nuclear antigen (PCNA), my colleagues 
and I found a similar low level of cell proliferation in 
human coronary arteries, normal and atherosclerotic 
(18), with most arteries displaying a 0% to 1% labeling 
index, but with occasional intimas displaying as much 
as a 5% labeling index. We have also seen similar lev- 
els of cell proliferation in advanced carotid plaques, in 
samples of restenotic coronary intimas obtained by ath- 
erectomy catheter, and in samples of human coronary 
transplant arteriosclerosis (unpublished observations). 
These levels are much lower than the 30% to 50% 
maximal levels seen after balloon catheter injury in the 
rat (17). The human artery measurements, however, 
are in concert with levels of cell proliferation seen with 
hypercholesterolemia models of atherosclerosis (19- 
25). 
A comparison of these two animal models of intimal 
thickening reveals differing time courses and spatial 
patterns of cell proliferation. Thus balloon injury to the 
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Table 1. Human Vascular, Intimal Proliferation Summary 
Vessel Approx. PCNA” Index Max. PCNA Index 
Int. Mammary ArLb O%-0.3% 0.3% 
Coronary DIT’ 0%-l% 1.2% 
Coronary Plaque 0%-l% 4.7% 
Carotid Plaque 0%-l% I .O% 
Coronary Restenosisd 0%-l% * 
Cor. Transpl. Arterio.’ 0%-l% 1: 
AV Dialysis Shunt‘ 5%-300/o 37.8%* 
“Proliferative activity is expressed as a percentage of cells displaying 
proliferating cell nuclear antigen (PCNA) immunoreactivity. 
models); (b) several similar episodes of brief prolifer- 
ative bursts caused by repeated injuries; and (c) a slow, 
indolent growth pattern similar to that in the hyper- 
cholesterolemia models. Perhaps in the future newer, 
noninvasive imaging modalities (such as magnetic res- 
onance imaging), which are able to visualize the whole 
plaque and its constituents (35) rather than primarily 
lumen size, will be used to serially follow individual 
human lesions to allow discrimination among these 
possible modalities of plaque growth. 
bIntemal mammary artery segments. ‘Coronary artery diffuse intimal 
thickening. dCoronary restenosis tissue obtained via atherectomy cathe- 
ter. ‘Coronary arteries obtained from transplanted hearts. ‘Intima from 
arteriovenous hemodialysis shunts, taken from the vein anastomosis site. 
*Studies still in progress. 
rat carotid artery causes an abrupt, large increase in 
proliferative index, from a control level on the order 
of 0.04%, to a maximum on the order of 30% to 50% 
in the media within 1 to 2 days of injury. The subse- 
quently developing neointima has an even higher la- 
beling index, and after 2 weeks the bulk of proliferative 
activity remains localized to the region adjacent to the 
lumen. This is then followed by a gradual decline in 
proliferative index such that, by 8 weeks after injury, 
this overall intimal proliferative index is less than 
1%. In contrast, cell labeling appears to be more ran- 
dom in location in the hypercholesterolemia animal 
models. Although increased proliferative activity can 
be detected in pigs within days after the start of a 
cholesterol-rich diet (26), no proliferative indices above 
5% have been described during the evolution of ath- 
erosclerotic lesions induced by hypercholesterolemia 
alone (19-25). Admittedly these hypercholesterole- 
mia models may not have been sampled specifically for 
ongoing proliferative activity as frequently as were the 
balloon injury models. Nevertheless the data suggest a 
slow-growing, indolent proliferative response, which is 
able to produce significantly stenotic lesions in several 
months to a few years. Such models may thus be more 
representative of human atherosclerosis development, 
which takes several years before it can become prev- 
alent at autopsy (27-30). Such one-time observation 
autopsy studies, however, do not address the actual 
rate of development of individual atherosclerotic 
plaques. Individual plaques may differ in their rates of 
growth, as has been suggested by some serial angio- 
graphic and Doppler ultrasound studies (31-34). Thus 
at least three patterns of human atherosclerotic plaque 
development and growth can be proposed, and these 
are diagrammed in Figure 1: (a) a single, brief prolif- 
erative burst associated with some injury at an unspe- 
cified time and followed by a long, minimal-to-absent 
proliferative phase (analogous to the balloon injury 
Of further interest is the detection of cell prolifer- 
ation among monocyte/macrophage cells as well as 
among smooth muscle cells (18,36). Such macrophage 
proliferative activity has also been recently been seen 
in rabbit hypercholesterolemia models using either tri- 
tiated thymidine labeling (23) or colchicine mitotic ar- 
rest (37). Recently the presence of mRNA for the 
colony stimulating factors (m-CSF) and receptor (fms) 
in primate and human plaques (5,6,38,39) suggested an 
intricate network controlling inflammatory cell prolif- 
eration in human atherosclerosis as well. Lympho- 
cyte proliferation is also a possibility, and whether 
these different cell types and smooth muscle cells have 
similar or different patterns of proliferation is currently 
unknown. 
Preliminary data have indicated a particularly high 
proliferative index in certain arteriovenous shunts used 
for dialysis in renal failure patients. In at least those 
shunts with a piece of polytetrafluoroethylene (PTFE, 
Gore-Tex) graft placed between the artery and vein, 
Figure 1. Graphic depiction of three possible patterns of cell 
proliferation in the development and progression of human 
atherosclerosis: (A) single injury (balloon injury) pattern 
with an initial burst of proliferative activity followed by a 
long latent period; (B) intermittent injury pattern, in which 
each injury has its own burst of proliferative activity followed 
by a latent period; and (C) an indolent, low-level prolifera- 
tive pattern as seen in hypercholesterolemia models. 
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the most prominent intimal thickening occurs at the 
graft-vein anastomosis region and is composed of pre- 
dominantly smooth muscle cells (40). In a sample of 
such grafts, my colleagues and I recently saw prolifer- 
ative indices in the 5% to 30% range (unpublished ob- 
servations). The growth factors responsible for such 
growth are not clear, but they could be related to the 
release of platelet factors on the graft or to growth 
factor production by cells around this graft material. 
Indeed PDGF gene expression has been reported to be 
associated with PTFE graft material (41). Alternatively 
growth could be driven by thrombin activation on the 
graft, considering that thrombin is a mitogen for 
smooth muscle cells (42). The time course of prolifer- 
ation in this arteriovenous shunt lesion is not known. 
Future studies will determine what correlations, if 
any, exist among the spatial presence of growth factors 
and cell proliferation in the development of human ar- 
terial and venous intimal lesions. These may be tech- 
nically difficult from a pathological point of view, 
because the investigator will have to keep track of at 
least three tissue markers in the same tissue location: 
proliferative activity, specific growth factor, and the cell 
types appropriate for the specific growth factor. Other 
important variables, such as the types of growth factor 
receptors the presumed target cells possess, will also 
have to be considered. 
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